RIPK3 and breast carcinoma: As the activation of MLKL is associated with its phosphorylation by RIPK3 [5], the effect of DS variants on the phospho-MLKL level in breast cancer cells might probably be mediated through the stimulatory impact of these glycans on the kinase activity.